REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences.
The Stifel 2024 Healthcare Conference (New York, NY)
The Jefferies London Healthcare Conference (London, UK)
The 15th Annual Craig-Hallum Alpha Select Conference (New York, NY)
The Stephens Annual Investment Conference (Nashville, TN)
Live webcasts of each fireside chat will be available on the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay of each fireside chat will be archived for 90 days following the presentation date.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Lauren Musto
(650) 421-8205
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.28 |
| Daily Change: | 0.16 3.12 |
| Daily Volume: | 2,665,497 |
| Market Cap: | US$429.690M |
November 14, 2024 November 11, 2024 October 31, 2024 October 24, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
